Roivant Sciences's three largest insider shareholders as of March 23, 2026 are Pharma Technologies Ltd. Dexcel (TenPercentOwner, 102.85Mn shares), Investments (Uk) Ltd Svf (TenPercentOwner, 73.03Mn shares), Chemical Co., Ltd. Sumitomo (TenPercentOwner, 71.25Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Investments (Uk) Ltd Svf | 0 | 73,031,667 | 02 Oct, 2023 | |
| Chemical Co., Ltd. Sumitomo | 0 | 71,251,083 | 26 Jun, 2023 | |
| Mayukh Sukhatme | President Cio | 18,836,547 | 0 | 11 Feb, 2026 |
| Frank Torti | President And Vant Chair | 13,736,547 | 0 | 23 Feb, 2026 |
| Eric Venker | President Immunovant Ceo | 1,647,546 | 0 | 19 Mar, 2026 |
| Rakhi Kumar | Chief Accounting Officer | 162,306 | 0 | 24 Feb, 2025 |
| Melissa B, Epperly | 15,804 | 0 | 18 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 17 Mar, 2026 | Eric Venker | Common Shares | A | 200,000 | $3.85 | 1,847,546 | D | M |
| 17 Mar, 2026 | Eric Venker | Common Shares | D | 200,000 | $28.24 | 1,647,546 | D | S |
| 17 Mar, 2026 | Eric Venker | Stock Option (Right to Buy) | D | 200,000 | $0.00 | 4,844,834 | D | M |
| 16 Mar, 2026 | Melissa B, Epperly | Common Shares | D | 41,861 | $28.68 | 15,804 | D | S |
| 20 Feb, 2026 | Eric Venker | Common Shares | D | 7,051 | $27.15 | 1,647,546 | D | F |
| 19 Feb, 2026 | Frank Torti | Common Shares | A | 1,400,000 | $3.85 | 15,136,547 | D | M |
| 19 Feb, 2026 | Frank Torti | Common Shares | D | 1,400,000 | $27.42 | 13,736,547 | D | S |
| 20 Feb, 2026 | Frank Torti | Common Shares | A | 1,012,610 | $3.85 | 14,749,157 | D | M |
| 20 Feb, 2026 | Frank Torti | Common Shares | D | 1,012,610 | $27.15 | 13,736,547 | D | S |
| 23 Feb, 2026 | Frank Torti | Common Shares | A | 587,390 | $3.85 | 14,323,937 | D | M |
| 23 Feb, 2026 | Frank Torti | Common Shares | D | 587,390 | $27.51 | 13,736,547 | D | S |
| 19 Feb, 2026 | Frank Torti | Stock Option (Right to Buy) | D | 1,400,000 | $0.00 | 4,626,184 | D | M |
| 20 Feb, 2026 | Frank Torti | Stock Option (Right to Buy) | D | 1,012,610 | $0.00 | 3,613,574 | D | M |
| 23 Feb, 2026 | Frank Torti | Stock Option (Right to Buy) | D | 587,390 | $0.00 | 3,026,184 | D | M |
| 13 Feb, 2026 | Eric Venker | Common Shares | A | 200,000 | $3.85 | 1,854,597 | D | M |
| 13 Feb, 2026 | Eric Venker | Common Shares | D | 200,000 | $26.49 | 1,654,597 | D | S |
| 13 Feb, 2026 | Eric Venker | Stock Option (Right to Buy) | D | 200,000 | $0.00 | 5,044,834 | D | M |
| 09 Feb, 2026 | Mayukh Sukhatme | Common Shares | A | 651,558 | $12.68 | 19,488,105 | D | M |
| 09 Feb, 2026 | Mayukh Sukhatme | Common Shares | D | 339,441 | $26.47 | 19,148,664 | D | S |
| 09 Feb, 2026 | Mayukh Sukhatme | Common Shares | D | 312,117 | $26.47 | 18,836,547 | D | J |